Other risk factors that may increase vulnerability include: Long duration of diabetes (typically more than 10 years) Poor glycaemic control prior to starting GLP-1 therapy (HbA1c significantly above target) Rapid reduction in HbA1c (a drop of more than 2 percentage points [22 mmol/mol] within 36 months) Concurrent hypertension , especially if poorly controlled Diabetic kidney disease (nephropathy), which often correlates with retinopathy severity Previous history of retinal treatment (laser photocoagulation or intravitreal injections) People with type 2 diabetes but no retinopathy appear to have minimal risk of retinopathy progression based on current evidence
Does Insurance Cover Peptide Therapy
Delivery took a couple of days longer than expected, but the quality more than made up for it
That makes it a much milder and safer option for recovery and performance enhancement
But watching most of the progress reverse is demoralizing enough to feel like failure
Dexcom Flex has been designed to support people earlier in their type 2 diabetes journey, delivering a more tailored experience while maintaining the accuracy and reliability associated with Dexcom technology. Alexander Frhlich, VP and GM, DACH at Dexcom, said: Launching Dexcom Flex in Germany reflects our continued focus on expanding access to CGM